Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Recruiting 2Active not recruiting 2

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 107Lymphoid 87CNS 80Gastrointestinal 79Thoracic 54Breast 51Head & Neck 46Gynecologic 40Other hematologic neoplasm 34Sarcoma 32Plasma cell 29Dermatologic 26Tumor-Agnostic 19Endocrine 15Myeloid 10NET 8Other solid neoplasm 4Other neoplasm 2Other 1

Conditions

Malignant Solid Neoplasm 1Malignant Female Reproductive System Neoplasm 1Anatomic Stage III Breast Cancer AJCC v8 1Advanced Solid Tumor 1

Interventions

pembrolizumab 35Injections 28Pemetrexed 15Interviews as Topic 15tislelizumab 13Cisplatin 13Carboplatin 13Specimen Handling 12Bevacizumab 11atezolizumab 10Nivolumab 10Practice Guidelines as Topic 9Educational Status 9Standard of Care 8Oxaliplatin 8Methods 8Fluorouracil 8Early Intervention, Educational 8Docetaxel 7Cyclophosphamide 7Cetuximab 7Capecitabine 7toripalimab 6sotorasib 6Paclitaxel 6Leucovorin 6olaparib 5fludarabine 5Platinum 5Ipilimumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Magnetic Resonance Spectroscopy × Other solid neoplasm × 90 days × Clear all
NCT05599048 2026-05-27

Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors

University of California, San Francisco

Phase 1/2 Recruiting
65 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT06126276 2026-05-13

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
70 enrolled
Other solid neoplasm

Malignant Female Reproductive System Neoplasm

NCT06351371 2026-04-14

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
35 enrolled 10 charts
Other solid neoplasm

Malignant Solid Neoplasm

NCT02453620 2026-04-13

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
57 enrolled
BreastOther solid neoplasm

Anatomic Stage III Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡